Nutrition interventions to treat low muscle mass in cancer

Carla M Prado, Sarah A Purcell, Alessandro Laviano, Carla M Prado, Sarah A Purcell, Alessandro Laviano

Abstract

Many patients with cancer experience poor nutritional status, which detrimentally impacts clinical outcomes. Poor nutritional status in cancer is primarily manifested by severe muscle mass (MM) depletion, which may occur at any stage (from curative to palliative) and often co-exists with obesity. The objective of this article was to discuss gaps and opportunities related to the role of nutrition in preventing and reversing low MM in cancer. It also provides a narrative review of relevant nutritional interventions for patients capable of oral intake. The impact of nutrition interventions to prevent/treat low MM in cancer is not well understood, potentially due to the limited number of studies and of clinically viable, accurate body composition assessment tools. Additionally, the type of study designs, inclusion criteria, length of intervention, and choice of nutritional strategies have not been optimal, likely underestimating the anabolic potential of nutrition interventions. Nutrition studies are also often of short duration, and interventions that adapt to the metabolic and behavioural changes during the clinical journey are needed. We discuss energy requirements (25-30 kcal/kg/day) and interventions of protein (1.0-1.5 g/kg/day), branched-chain amino acids (leucine: 2-4 g/day), β-hydroxy β-methylbutyrate (3 g/day), glutamine (0.3 g/kg/day), carnitine (4-6 g/day), creatine (5 g/day), fish oil/eicosapentanoic acid (2.0-2.2 g/day EPA and 1.5 g/day DHA), vitamin/minerals (e.g. vitamin D: 600-800 international units per day), and multimodal approaches (nutrition, exercise, and pharmaceutical) to countermeasure low MM in cancer. Although the evidence is variable by modality type, interventions were generally not specifically studied in the context of cancer. Understanding patients' nutritional requirements could lead to targeted prescriptions to prevent or attenuate low MM in cancer, with the overall aim of minimizing muscle loss during anti-cancer therapy and maximizing muscle anabolism during recovery. It is anticipated that this will, in turn, improve overall health and prognostication including tolerance to treatment and survival. However, oncology-specific interventions with more robust study designs are needed to facilitate these goals.

Keywords: Body composition; Cancer; Intervention; Low muscle mass; Myopenia; Nutrition; Protein; Sarcopenia.

Conflict of interest statement

The authors declare that they have no relevant conflicts of interest.

© 2020 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society on Sarcopenia, Cachexia and Wasting Disorders.

Figures

Figure 1
Figure 1
Causes and potential nutrition treatments for low muscle mass in cancer. Items on the left negatively impact muscle mass, while items on the right are under consideration for treating low muscle mass. Amounts on the right are either current recommendations (where available) or what research suggests might be sufficient for altering body composition. Interventions are focused on patients capable of oral nutrition intake. AAs, amino acids; DHA, docosahexaenoic acid; EPA, eicosapentanoic acid; HMB, β‐hydroxy β‐methylbutyrate; IU, international units.
Figure 2
Figure 2
Comparison of theoretical energy recommendations among patients with colorectal cancer. n = 83 patients with newly diagnosed stage I–IV colorectal cancer had resting energy expenditure (REE) measured by indirect calorimetry (metabolic cart). Each quintuplicate of shapes represents one patient. REE was multiplied by a physical activity level of 1.24 and 1.4 according to previous research in cancer50 and energy recommendations put forth by FAO/WHO/UNU for adults,51 respectively. Energy requirements were also estimated by multiplying body weight (in kg) by 25 and 30 as per oncology‐specific recommendation put forth by The European Society for Clinical Nutrition and Metabolism (ESPEN).18
Figure 3
Figure 3
Selected factors impacting body composition in the context of cancer. Nutrition is essential part of supporting optimal muscle mass in these patients.

References

    1. Bazzan AJ, Newberg AB, Cho WC, Monti DA. Diet and nutrition in cancer survivorship and palliative care. Evid Based Complement Alternat Med 2013;2013:917647.
    1. Ravasco P, Monteiro‐Grillo I, Camilo ME. Does nutrition influence quality of life in cancer patients undergoing radiotherapy? Radiother Oncol 2003;67:213–220.
    1. Prado CMM. Body composition in chemotherapy: the promising role of CT scans. Curr Opin Clin Nutr Metab Care 2013;16:525–533.
    1. Prado CMM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population‐based study. Lancet Oncol 2008;9:629–635.
    1. Prado CMM, Lieffers JR, Bowthorpe L, Baracos VE, Mourtzakis M, McCargar LJ. Sarcopenia and physical function in overweight patients with advanced cancer. Can J Diet Pract Res 2013;74:69–74.
    1. Prado CMM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, et al. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009;15:2920–2926.
    1. Prado CMM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, et al. Body composition as an independent determinant of 5‐fluorouracil‐based chemotherapy toxicity. Clin Cancer Res 2007;13:3264–3268.
    1. von Haehling S, Morley JE, Anker SD. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 2010;1:129–133.
    1. Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539–1547.
    1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–495.
    1. Demark‐Wahnefried W, Peterson BL, Winer EP, Marks L, Aziz N, Marcom PK, et al. Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2001;19:2381–2389.
    1. Brown JC, Caan BJ, Meyerhardt JA, Weltzien E, Xiao J, Cespedes Feliciano EM, et al. The deterioration of muscle mass and radiodensity is prognostic of poor survival in stage I‐III colorectal cancer: a population‐based cohort study (C‐SCANS). J Cachexia Sarcopenia Muscle 2018;9:664–672.
    1. Prado CM, Sawyer MB, Ghosh S, Lieffers JR, Esfandiari N, Antoun S, et al. Central tenet of cancer cachexia therapy: do patients with advanced cancer have exploitable anabolic potential? Am J Clin Nutr 2013;98:1012–1019.
    1. Caan BJ, Meyerhardt JA, Kroenke CH, Alexeeff S, Xiao J, Weltzien E, et al. Explaining the obesity paradox: the association between body composition and colorectal cancer survival (C‐SCANS Study). Cancer Epidemiol Biomarkers Prev 2017;26:1008–1015.
    1. Caan BJ, Cespedes Feliciano EM, Prado CM, Alexeeff S, Kroenke CH, Bradshaw P, et al. Association of muscle and adiposity measured by computed tomography with survival in patients with nonmetastatic breast cancer. JAMA Oncol 2018;4:798–804.
    1. Chiu T‐Y, Hu W‐Y, Chuang R‐B, Cheng Y‐R, Chen C‐Y, Wakai S. Terminal cancer patients' wishes and influencing factors toward the provision of artificial nutrition and hydration in Taiwan. J Pain Symptom Manage 2004;27:206–214.
    1. Bossola M, Pacelli F, Rosa F, Tortorelli A, Battista DG. Review: does nutrition support stimulate tumor growth in humans? Nutr Clin Pract 2011;26:174–180.
    1. Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr 2017;36:11–48.
    1. Arends J, Bodoky G, Bozzetti F, Fearon K, Muscaritoli M, Selga G, et al. ESPEN guidelines on enteral nutrition: non‐surgical oncology. Clin Nutr 2006;25:245–259.
    1. Kurk S, Peeters P, Stellato R, Dorresteijn B, de Jong P, Jourdan M, et al. Skeletal muscle mass loss and dose‐limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle Published Online First: May 2019;10.1002/jcsm.12436.
    1. Judge SM, Nosacka RL, Delitto D, Gerber MH, Cameron ME, Trevino JG, et al. Skeletal muscle fibrosis in pancreatic cancer patients with respect to survival. JNCI Cancer Spectr 2019;2:10.1093/jncics/pky043.
    1. Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition 2019;67–68:110539.
    1. Prado CM, Cushen SJ, Orsso CE, Ryan AM. Sarcopenia and cachexia in the era of obesity: clinical and nutritional impact. Proc Nutr Soc 2016;75:1–11.
    1. van der Werf A, Langius JAE, de van der Schueren MAE, Nurmohamed SA, van der Pant KAMI, Blauwhoff‐Buskermolen S, et al. Percentiles for skeletal muscle index, area and radiation attenuation based on computed tomography imaging in a healthy Caucasian population. Eur J Clin Nutr 2018;72:288–296.
    1. Derstine BA, Holcombe SA, Ross BE, Wang NC, Su GL, Wang SC. Skeletal muscle cutoff values for sarcopenia diagnosis using T10 to L5 measurements in a healthy US population. Sci Rep 2018;8:11369.
    1. Davis CD, Ohlhorst S. The future of nutrition research at the National Institutes of Health. Adv Nutr 2014;5:537–540.
    1. Freudenheim JL. Study design and hypothesis testing: issues in the evaluation of evidence from research in nutritional epidemiology. Am J Clin Nutr 1999;69:1315s–1321s.
    1. Blauwhoff‐Buskermolen S, Versteeg KS, de van der Schueren MA, den Braver NR, Berkhof J, Langius JA, et al. Loss of muscle mass during chemotherapy is predictive for poor survival of patients with metastatic colorectal cancer. J Clin Oncol 2016;20:1339–1344.
    1. Schmitz KH, Ahmed RL, Hannan PJ, Yee D. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin‐like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev 2005;14:1672–1680.
    1. Thomas GA, Cartmel B, Harrigan M, Fiellin M, Capozza S, Zhou Y, et al. The effect of exercise on body composition and bone mineral density in breast cancer survivors taking aromatase inhibitors. Obesity 2017;25:346–351.
    1. Fearon KCH, Argiles JM, Baracos VE, Bernabei R, Coats AJS, Crawford J, et al. Request for regulatory guidance for cancer cachexia intervention trials. J Cachexia Sarcopenia Muscle 2015;6:272–274.
    1. Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 2011;117:1775–1782.
    1. Deutz NEP, Safar A, Schutzler S, Memelink R, Ferrando A, Spencer H, et al. Muscle protein synthesis in cancer patients can be stimulated with a specially formulated medical food. Clin Nutr 2011;30:759–768.
    1. Fearon KCH, Barber MD, Moses AG, Ahmedzai SH, Taylor GS, Tisdale MJ, et al. Double‐blind, placebo‐controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol 2006;24:3401–3407.
    1. Orrevall Y, Tishelman C, Permert J, Cederholm T. The use of artificial nutrition among cancer patients enrolled in palliative home care services. Palliat Med 2009;23:556–564.
    1. Fearon KC. Cancer cachexia: developing multimodal therapy for a multidimensional problem. Eur J Cancer 2008;44:1124–1132.
    1. Purcell SA, Elliott SA, Baracos VE, Chu QSC, Prado CM. Key determinants of energy expenditure in cancer and implications for clinical practice. Eur J Clin Nutr 2016;70:1230–1238.
    1. Ryan AM, Power DG, Daly L, Cushen SJ, Ni Bhuachalla E, Prado CM. Cancer‐associated malnutrition, cachexia and sarcopenia: the skeleton in the hospital closet 40 years later. Proc Nutr Soc 2016; 75;(2):1–13.
    1. Butterworth CEJ. The skeleton in the hospital closet. Nutr Today 1974;9:4–8.
    1. Ebadi M, Martin L, Ghosh S, Field CJ, Lehner R, Baracos VE, et al. Subcutaneous adiposity is an independent predictor of mortality in cancer patients. Br J Cancer 2017;117:148–155.
    1. Gonzalez MC, Pastore CA, Orlandi SP, Heysmfield SB. Obesity paradox in cancer: new insights provided by body composition. Am J Clin Nutr 2014;99:999–1005.
    1. Prado CM, Gonzalez MC, Heymsfield SB. Body composition phenotypes and obesity paradox. Curr Opin Clin Nutr Metab Care 2015;18:535–551.
    1. Jouinot A, Vazeille C, Durand JP, Huillard O, Boudou‐Rouquette P, Coriat R, et al. Resting energy expenditure in the risk assessment of anticancer treatments. Clin Nutr 2018;37:558–565.
    1. Purcell SA, Wallengren O, Baracos VE, Lundholm K, Iresjo B‐M, Chu QSC, et al. Determinants of change in resting energy expenditure in patients with stage III/IV colorectal cancer. Clin Nutr Published Online First: March 2019;10.1016/j.clnu.2018.12.038.
    1. Cao D, Wu G, Zhang B, Quan Y, Wei J, Jin H, et al. Resting energy expenditure and body composition in patients with newly detected cancer. Clin Nutr 2010;29:72–77.
    1. Fearon KCH, von Meyenfeldt MF, Moses AGW, van Geenen R, Roy A, Gouma DJ, et al. Effect of a protein and energy dense n‐3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut 2003;52:1479–1486.
    1. Skipworth RJ, Stene GB, Dahele M, Hendry PO, Small AC, Blum D, et al. Patient‐focused endpoints in advanced cancer: criterion‐based validation of accelerometer‐based activity monitoring. Clin Nutr 2011;30:812–821.
    1. Gibney E, Elia M, Jebb SA, Murgatroyd P, Jennings G. Total energy expenditure in patients with small‐cell lung cancer: results of a validated study using the bicarbonate‐urea method. Metabolism 1997;46:1412–1417.
    1. Hayes S, Davies PS, Parker T, Bashford J. Total energy expenditure and body composition changes following peripheral blood stem cell transplantation and participation in an exercise programme. Bone Marrow Transpl 2003;31:331–338.
    1. Purcell SA, Elliott SA, Walter PJ, Preston T, Cai H, Skipworth RJ, et al. Total energy expenditure in patients with colorectal cancer: associations with body composition, physical activity, and energy recommendations. Am J Clin Nutr 2019; In press. 110(2):367–376.
    1. Moses AW, Slater C, Preston T, Barber MD, Fearon KC. Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n‐3 fatty acids. Br J Cancer 2004;90:996–1002.
    1. Food and Agricultural Organization of the United Nations/World Health Organization/United Nations University . Human Energy Requirements. Report of a Joint FAO/WHO/UNU Expert Consultation. Rome Italy. Accessed May 03, 2019 2001.
    1. Purcell SA, Elliott SA, Ryan AM, Sawyer MB, Prado CM. Accuracy of a portable on direct calorimeter for measuring resting energy expenditure in individuals with cancer. J Parenter Enter Nutr 2019;43:145–151.
    1. Purcell S, Thornberry R, Elliott SA, Panton L, Ormsbee MJ, Vieira ER, et al. Body composition, strength, and dietary intake of patients with hip or knee osteoarthritis. Can J Diet Pract Res 2016;77:10.3148/cjdpr-2015-037.
    1. Fujita S, Dreyer HC, Drummond MJ, Glynn EL, Cadenas JG, Yoshizawa F, et al. Nutrient signalling in the regulation of human muscle protein synthesis. J Physiol 2007;582:813–823.
    1. . No Title. Identifier NCT02788955. Protein Recomm. to Increase Muscle.
    1. Institutes of Medicine of the National Academies of Science Engineering and Medicine . Dietary reference intakes for energy, carbohydrates, fiber, fat, fatty acids, Cholesterol, protein, and amino acids. Washington, D.C., USA: 2004.
    1. Hutton JL, Martin L, Field CJ, Wismer WV, Bruera ED, Watanabe SM, et al. Dietary patterns in patients with advanced cancer: implications for anorexia‐cachexia therapy. Am J Clin Nutr 2006;84:1163–1170.
    1. Prado CM, Lieffers JR, Bergsten G, Mourtzakis M, Baracos VE, Reiman T, et al. Dietary patterns of patients with advanced lung or colorectal cancer. Can J Diet Pr Res 2012;73:e298–e303.
    1. Prado CMM, Mourtzakis M, Baracos V, Reiman T, Sawyer MB, McCargar LJ. Overweight and obese patients with solid tumors may have sarcopenia, poor prognosis and early features of cachexia. Int J Body Compos Res 2010;8:7–15.
    1. Engelen MP, Safar AM, Bartter T, Koeman F, Deutz NE. High anabolic potential of essential amino acid mixtures in advanced nonsmall cell lung cancer. Ann Oncol 2015;26:1960–1966.
    1. Geisler C, Prado C, Müller M. Inadequacy of body weight‐based recommendations for individual protein intake—lessons from body composition analysis. Nutrients 2017;9:23.
    1. Prado CM, Heymsfield SB. Lean tissue imaging: a new era for nutritional assessment and intervention. JPEN J Parenter Enter Nutr 2014;38:940–953.
    1. Omlin A, Blum D, Wierecky J, Haile SR, Ottery FD, Strasser F. Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case‐control study. J Cachexia Sarcopenia Muscle 2013;4:55–61.
    1. Patterson RE, Neuhouser ML, Hedderson MM, Schwartz SM, Standish LJ, Bowen DJ. Changes in diet, physical activity, and supplement use among adults diagnosed with cancer. J Am Diet Assoc 2003;103:323–328.
    1. Velentzis LS, Keshtgar MR, Woodside JV, Leathem AJ, Titcomb A, Perkins KA, et al. Significant changes in dietary intake and supplement use after breast cancer diagnosis in a UK multicentre study. Breast Cancer Res Treat 2011;128:473–482.
    1. Van Blarigan EL, Fuchs CS, Niedzwiecki D, Zhang S, Saltz LB, Mayer RJ, et al. Association of survival with adherence to the American Cancer Society Nutrition and Physical Activity Guidelines for cancer survivors after colon cancer diagnosis: the CALGB 89803/Alliance TrialAssociation of colon cancer survival with ACS Guideline Adher. JAMA Oncol 2018;4:783–790.
    1. Rock CL, Doyle C, Demark‐Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012;62:243–274.
    1. Op den Kamp CM, Langen RC, Haegens A, Schols AM. Muscle atrophy in cachexia: can dietary protein tip the balance? Curr Opin Clin Nutr Metab Care 2009;12:611–616.
    1. Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz‐Jentoft AJ, Dent E, et al. Sarcopenia: a time for action. An SCWD Position Paper. J Cachexia Sarcopenia Muscle 2019;0:10.1002/jcsm.12483.
    1. Wolfe RR, Miller SL, Miller KB. Optimal protein intake in the elderly. Clin Nutr 2008;27:675–684.
    1. Witard OC, Wardle SL, Macnaughton LS, Hodgson AB, Tipton KD. Protein considerations for optimising skeletal muscle mass in healthy young and older adults. Nutrients 2016;8:181.
    1. Fouladiun M, Korner U, Bosaeus I, Daneryd P, Hyltander A, Lundholm KG. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005;103:2189–2198.
    1. Deutz NEP, Bauer JM, Barazzoni R, Biolo G, Boirie Y, Bosy‐Westphal A, et al. Protein intake and exercise for optimal muscle function with aging: recommendations from the ESPEN Expert Group. Clin Nutr 2014;33:929–936.
    1. Bozzetti F, Bozzetti V. Is the intravenous supplementation of amino acid to cancer patients adequate? A critical appraisal of literature. Clin Nutr 2013;32:142–146.
    1. Bozzetti F. Nutritional support of the oncology patient. Crit Rev Oncol Hematol 2013;87:172–200.
    1. Tayek JA, Bistrian BR, Hehir DJ, Martin R, Moldawer LL, Blackburn GL. Improved protein kinetics and albumin synthesis by branched chain amino acid‐enriched total parenteral nutrition in cancer cachexia. A prospective randomized crossover trial. Cancer 1986;58:147–157.
    1. Hunter DC, Weintraub M, Blackburn GL, Bistrian BR. Branched chain amino acids as the protein component of parenteral nutrition in cancer cachexia. Br J Surg 1989;76:149–153.
    1. Nicastro H, Artioli GG, Costa Ados S, Solis MY, da Luz CR, Blachier F, et al. An overview of the therapeutic effects of leucine supplementation on skeletal muscle under atrophic conditions. Amino Acids 2011;40:287–300.
    1. White PJ, Newgard CB. Branched‐chain amino acids in disease. Science (80‐) 2019;363:582–583.
    1. Nissen SL, Abumrad NN. Nutritional role of the leucine metabolite β‐hydroxy β‐methylbutyrate (HMB). J Nutr Biochem 1997;8:300–311.
    1. Smith KL, Tisdale MJ. Increased protein degradation and decreased protein synthesis in skeletal muscle during cancer cachexia. Br J Cancer 1993;67:680–685.
    1. May PE, Barber A, D'Olimpio JT, Hourihane A, Abumrad NN. Reversal of cancer‐related wasting using oral supplementation with a combination of beta‐hydroxy‐beta‐methylbutyrate, arginine, and glutamine. Am J Surg 2002;183:471–479.
    1. Berk L, James J, Schwartz A, Hug E, Mahadevan A, Samuels M, et al. A randomized, double‐blind, placebo‐controlled trial of a β‐hydroxyl β‐methyl butyrate, glutamine, and arginine mixture for the treatment of cancer cachexia (RTOG 0122). Support Care Cancer 2008;16:1179–1188.
    1. Wada N, Kurokawa Y, Tanaka K, Miyazaki Y, Makino T, Takahashi T, et al. Perioperative nutritional support with β‐hydroxy‐β‐methylbutyrate, arginine, and glutamine in surgery for abdominal malignancies. Wounds a Compend Clin Res Pract 2018;30:251–256.
    1. Molfino A, Gioia G, Fanelli FR, Muscaritoli M. Beta‐hydroxy‐beta‐methylbutyrate supplementation in health and disease: a systematic review of randomized trials. Amino Acids 2013;45:1273–1292.
    1. Bear DE, Langan A, Dimidi E, Wandrag L, Harridge SDR, Hart N, et al. β‐Hydroxy‐β‐methylbutyrate and its impact on skeletal muscle mass and physical function in clinical practice: a systematic review and meta‐analysis. Am J Clin Nutr 2019;109:1119–1132.
    1. Bergstrom J, Furst P, Noree LO, Vinnars E. Intracellular free amino acid concentration in human muscle tissue. J Appl Physiol 1974;36:693–697.
    1. Gaurav K, Goel RK, Shukla M, Pandey M. Glutamine: a novel approach to chemotherapy‐induced toxicity. Indian J Med Paediatr Oncol 2012;33:13–20.
    1. Peterson DE, Jones JB, Petit RG 2nd. Randomized, placebo‐controlled trial of Saforis for prevention and treatment of oral mucositis in breast cancer patients receiving anthracycline‐based chemotherapy. Cancer 2007;109:322–331.
    1. Cerchietti LC, Navigante AH, Lutteral MA, Castro MA, Kirchuk R, Bonomi M, et al. Double‐blinded, placebo‐controlled trial on intravenous l‐alanyl‐l‐glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head‐and‐neck cancer. Int J Radiat Oncol Biol Phys 2006;65:1330–1337.
    1. Azman M, Mohd Yunus MR, Sulaiman S, Syed Omar SN. Enteral glutamine supplementation in surgical patients with head and neck malignancy: a randomized controlled trial. Head Neck 2015;37:1799–1807.
    1. Karlic H, Lohninger A. Supplementation of l‐carnitine in athletes: does it make sense? Nutrition 2004;20:709–715.
    1. Ringseis R, Keller J, Eder K. Mechanisms underlying the anti‐wasting effect of l‐carnitine supplementation under pathologic conditions: evidence from experimental and clinical studies. Eur J Nutr 2013;52:1421–1442.
    1. Kraft M, Kraft K, Gärtner S, Mayerle J, Simon P, Weber E, et al. l‐Carnitine‐supplementation in advanced pancreatic cancer (CARPAN)—a randomized multicentre trial. Nutr J 2012;11:52.
    1. Moore FD, Olesen KH, McMurrey JD, Parker HV, Ball MR, Boyden CM. The body cell mass and its supporting environment: body composition in health and in disease. Philadelphia, PA: Saunders; 1963. 10.1002/ajpa.1330220223.
    1. Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, et al. Efficacy of l‐carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition 2006;22:136–145.
    1. Thomas DT, Erdman KA, Burke LM. Position of the Academy of Nutrition and Dietetics, Dietitians of Canada, and the American College of Sports Medicine: nutrition and athletic performance. J Acad Nutr Diet 2016;116:501–528.
    1. Gualano B, Rawson ES, Candow DG, Chilibeck PD. Creatine supplementation in the aging population: effects on skeletal muscle, bone and brain. Amino Acids 2016;48:1793–1805.
    1. Fairman CM, Kendall KL, Hart NH, Taaffe DR, Galvão DA, Newton RU. The potential therapeutic effects of creatine supplementation on body composition and muscle function in cancer. Crit Rev Oncol Hematol 2019;133:46–57.
    1. Norman K, Stübler D, Baier P, Schütz T, Ocran K, Holm E, et al. Effects of creatine supplementation on nutritional status, muscle function and quality of life in patients with colorectal cancer—a double blind randomised controlled trial. Clin Nutr 2006;25:596–605.
    1. Lønbro S, Dalgas U, Primdahl H, Overgaard J, Overgaard K. Feasibility and efficacy of progressive resistance training and dietary supplements in radiotherapy treated head and neck cancer patients—the DAHANCA 25A study. Acta Oncol (Madr) 2013;52:310–318.
    1. Jatoi A, Steen PD, Atherton PJ, Moore DF, Rowland KM, Le‐Lindqwister NA, et al. A double‐blind, placebo‐controlled randomized trial of creatine for the cancer anorexia/weight loss syndrome (N02C4): an Alliance trial. Ann Oncol Off J Eur Soc Med Oncol 2017;28:1957–1963.
    1. Pappalardo G, Almeida A, Ravasco P. Eicosapentaenoic acid in cancer improves body composition and modulates metabolism. Nutrition 2015;31:549–555.
    1. van der Meij BS, Langius JAE, Smit EF, Spreeuwenberg MD, von Blomberg BME, Heijboer AC, et al. Oral nutritional supplements containing (n‐3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non‐small cell lung cancer during multimodality treatment. J Nutr 2010;140:1774–1780.
    1. Shirai Y, Okugawa Y, Hishida A, Ogawa A, Okamoto K, Shintani M, et al. Fish oil‐enriched nutrition combined with systemic chemotherapy for gastrointestinal cancer patients with cancer cachexia. Sci Rep 2017;7:4826.
    1. Solís‐Martínez O, Plasa‐Carvalho V, Phillips‐Sixtos G, Trujillo‐Cabrera Y, Hernández‐Cuellar A, Queipo‐García GE, et al. Effect of eicosapentaenoic acid on body composition and inflammation markers in patients with head and neck squamous cell cancer from a public hospital in Mexico. Nutr Cancer 2018;70:663–670.
    1. Read JA, Beale PJ, Volker DH, Smith N, Childs A, Clarke SJ. Nutrition intervention using an eicosapentaenoic acid (EPA)‐containing supplement in patients with advanced colorectal cancer. Effects on nutritional and inflammatory status: a phase II trial. Support care cancer Off J Multinatl Assoc Support Care Cancer 2007;15:301–307.
    1. Sanchez‐Lara K, Turcott JG, Juarez‐Hernandez E, Nunez‐Valencia C, Villanueva G, Guevara P, et al. Effects of an oral nutritional supplement containing eicosapentaenoic acid on nutritional and clinical outcomes in patients with advanced non‐small cell lung cancer: randomised trial. Clin Nutr 2014;33:1017–1023.
    1. Feijo PM, Rodrigues VD, Viana MS, Dos Santos MP, Abdelhay E, Viola JP, et al. Effects of omega‐3 supplementation on the nutritional status, immune, and inflammatory profiles of gastric cancer patients: a randomized controlled trial. Nutrition 2019;61:125–131.
    1. Aoyama T, Yoshikawa T, Ida S, Cho H, Sakamaki K, Ito Y, et al. Effects of perioperative Eicosapentaenoic acid‐enriched oral nutritional supplement on lean body mass after total gastrectomy for gastric cancer. J Cancer 2019;10:1070–1076.
    1. Daenen LGM, Cirkel GA, Houthuijzen JM, Gerrits J, Oosterom I, Roodhart JML, et al. Increased plasma levels of chemoresistance‐inducing fatty acid 16:4(n‐3) after consumption of fish and fish oil. JAMA Oncol 2015;1:350–358.
    1. Mazurak VC, Calder PC, van der Meij BS. Let them eat fishlet them eat fishletters. JAMA Oncol 2015;1:840.
    1. Baracos V. Let Them Eat FishLet Them Eat FishLetters. JAMA Oncol 2015;1:840–841.
    1. Hering J, Garrean S, Dekoj TR, Razzak A, Saied A, Trevino J, et al. Inhibition of proliferation by omega‐3 fatty acids in chemoresistant pancreatic cancer cells. Ann Surg Oncol 2007;14:3620–3628.
    1. Murphy RA, Mourtzakis M, Mazurak VC. n‐3 polyunsaturated fatty acids: the potential role for supplementation in cancer. Curr Opin Clin Nutr Metab Care 2012;15:246–251.
    1. de van der Schueren MAE, Laviano A, Blanchard H, Jourdan M, Arends J, Baracos VE. Systematic review and meta‐analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo (radio)therapy: current evidence and guidance for design of future trials. Ann Oncol Off J Eur Soc Med Oncol 2018;29:1141–1153.
    1. Strohle A, Zanker K, Hahn A. Nutrition in oncology: the case of micronutrients (review). Oncol Rep 2010;24:815–828.
    1. Mochamat CH, Marinova M, Kaasa S, Stieber C, Conrad R, Radbruch L et al. A systematic review on the role of vitamins, minerals, proteins, and other supplements for the treatment of cachexia in cancer: a European Palliative Care Research Centre cachexia project. J Cachexia Sarcopenia Muscle 2017;8:25–39.
    1. Norman HA, Butrum RR, Feldman E, Heber D, Nixon D, Picciano MF, et al. The role of dietary supplements during cancer therapy. J Nutr 2003;133:3794S–3799S.
    1. Rondanelli M, Klersy C, Terracol G, Talluri J, Maugeri R, Guido D, et al. Whey protein, amino acids, and vitamin D supplementation with physical activity increases fat‐free mass and strength, functionality, and quality of life and decreases inflammation in sarcopenic elderly. Am J Clin Nutr 2016;103:830–840.
    1. Bauer JM, Verlaan S, Bautmans I, Brandt K, Donini LM, Maggio M, et al. Effects of a vitamin D and leucine‐enriched whey protein nutritional supplement on measures of sarcopenia in older adults, the PROVIDE study: a randomized, double‐blind, placebo‐controlled trial. J Am Med Dir Assoc 2015;16:740–747.
    1. Visser M, Deeg DJ, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin Endocrinol Metab 2003;88:5766–5772.
    1. Fuller JC Jr, Baier S, Flakoll P, Nissen SL, Abumrad NN, Rathmacher JA. Vitamin D status affects strength gains in older adults supplemented with a combination of β‐hydroxy‐β‐methylbutyrate, arginine, and lysine: a cohort study. JPEN J Parenter Enter Nutr 2011;35:757–762.
    1. Price KAR. Hydration in cancer patients. Curr Opin Support Palliat Care 2010;4:276–280.
    1. Sawka MN. Physiological consequences of hypohydration: exercise performance and thermoregulation. Med Sci Sports Exerc 1992;24:657–670.
    1. Hargreaves M, Febbraio M. Limits to exercise performance in the heat. Int J Sports Med 1998;19:S115–S116.
    1. Giulivi C, Ramsey J. On fuel choice and water balance during migratory bird flights. Int Biol Rev 2015;2015.
    1. Gerson AR, Guglielmo CG. Flight at low ambient humidity increases protein catabolism in migratory birds. Science (80‐) 2011;333:1434–1436.
    1. Yoo J‐I, Choi H, Song S‐Y, Park K‐S, Lee D‐H, Ha Y‐C. Relationship between water intake and skeletal muscle mass in elderly Koreans: a nationwide population‐based study. Nutrition 2018;53:38–42.
    1. Institutes of Medicine of the National Academies of Science Engineering and Medicine . Dietary reference intakes for water, potassium, sodium, chloride, and sulfate. Washington, D.C. 2005.
    1. Dreyer HC, Drummond MJ, Pennings B, Fujita S, Glynn EL, Chinkes DL, et al. Leucine‐enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. Am J Physiol Metab 2008;294:E392–E400.
    1. Kumar V, Atherton P, Smith K, Rennie MJ. Human muscle protein synthesis and breakdown during and after exercise. J Appl Physiol 2009;106:2026–2039.
    1. Heyland DK, Stapleton RD, Mourtzakis M, Hough CL, Morris P, Deutz NE, et al. Combining nutrition and exercise to optimize survival and recovery from critical illness: conceptual and methodological issues. Clin Nutr 2016;35:1196–1206.
    1. Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, et al. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int 2017;28:1817–1833.
    1. Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al No Title. SEER Cancer Stat. Rev. 1975‐2016. Natl. Cancer Institute, Bethesda, MD. 2019 (accessed 24 May2019).
    1. Danai LV, Babic A, Rosenthal MH, Dennstedt EA, Muir A, Lien EC, et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 2018;558:600–604.
    1. Mantovani G, Madeddu C, Maccio A, Gramignano G, Lusso MR, Massa E, et al. Cancer‐related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. Cancer Epidemiol Biomarkers Prev 2004;13:1651–1659.
    1. Maccio A, Madeddu C, Gramignano G, Mulas C, Floris C, Sanna E, et al. A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. Gynecol Oncol 2012;124:417–425.
    1. . Multimodal intervention for cachexia in advanced cancer patients undergoing chemotherapy (MENAC). NCT02330926.
    1. Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, et al. A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle 2017;8:778–788.
    1. Winter A, MacAdams J, Chevalier S. Normal protein anabolic response to hyperaminoacidemia in insulin‐resistant patients with lung cancer cachexia. Clin Nutr 2012;31:765–773.
    1. MacDonald AJ, Johns N, Stephens N, Greig C, Ross JA, Small AC, et al. Habitual myofibrillar protein synthesis is normal in patients with upper GI cancer cachexia. Clin Cancer Res 2015;21:1734–1740.
    1. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review of current practice and editorial policy. BMC Med Res Methodol 2010;10:67.
    1. Ebadi M, Mazurak VC. Evidence and mechanisms of fat depletion in cancer. Nutrients 2014;6:5280–5297.
    1. Daas SI, Rizeq BR, Nasrallah GK. Adipose tissue dysfunction in cancer cachexia. J Cell Physiol 2019;234:13–22.
    1. von Haehling S, Morley JE, Coats AJS, Anker SD. Ethical guidelines for publishing in the journal of cachexia, sarcopenia and muscle: update 2017. J. Cachexia. Sarcopenia Muscle. 2017;8:1081–1083.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi